

Appendix C



US005096890A

REEXAMINATION CERTIFICATE (2512th)

United States Patent [19]

[11] B1 5,096,890

Cross et al.

[45] Certificate Issued Mar. 28, 1995

[54] PYRROLIDINE DERIVATIVES

[75] Inventors: Peter E. Cross, Canterbury;
Alexander R. MacKenzie, Deal, both
of England

[73] Assignee: Pfizer Inc., New York, N.Y.

Reexamination Request:

No. 90/003,394, Apr. 11, 1994

Reexamination Certificate for:

Patent No.: 5,096,890
Issued: Mar. 17, 1992
Appl. No.: 493,068
Filed: Mar. 13, 1990

[30] Foreign Application Priority Data

Mar. 17, 1989 [GB] United Kingdom 8906166

[51] Int. Cl.⁶ A61K 31/40; C07D 207/08

[52] U.S. Cl. 514/422; 514/255;
514/340; 546/275; 548/568; 544/408; 544/336

[58] Field of Search 548/527, 526, 525, 566,
548/568, 572; 546/208; 544/408, 336; 514/422,
340, 255

[56]

References Cited

U.S. PATENT DOCUMENTS

4,810,713 3/1989 Yanni et al. 514/317
4,950,674 8/1990 Yanni et al. 514/317

FOREIGN PATENT DOCUMENTS

0235463 9/1987 European Pat. Off. .


OTHER PUBLICATIONS

Goodman and Gilman "The Pharmacological Basis of
Therapeutics" Pergamon Press, (1990) pp. 122-126.
Katritzky et al "Comprehensive Heterocyclic Chemis-
try" Pergamon Press (1984) vol. 3, pp. 943, 959-960.

Primary Examiner—Celia Chang

[57] ABSTRACT

Compounds of the formula



wherein R, Y and R¹ are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.

**REEXAMINATION CERTIFICATE
ISSUED UNDER 35 U.S.C. 307**

AS A RESULT OF REEXAMINATION, IT HAS
BEEN DETERMINED THAT:

NO AMENDMENTS HAVE BEEN MADE TO
THE PATENT

5 The patentability of claims 1-10 are confirmed.

* * * * *

10

15

20

25

30

35

40

45

50

55

60

65